Needham & Company Reiterates Buy on Theravance Biopharma (TBPH) Following Conference Call

February 28, 2017 7:07 AM

Needham & Company reiterated a Buy rating and $40.00 price target on Theravance Biopharma (NASDAQ: TBPH) following the company's 4Q ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found